Niagen Bioscience Inc

Niagen Bioscience Inc

NAGE - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$163.54M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Niagen Bioscience IncNiagen Bioscience Inc16.3-12%--
$10.00

Target Price by Analysts

390.2% upsideNiagen Bioscience Target Price DetailsTarget Price
$-0.50

Current Fair Value

124.3% downside

Overvalued by 124.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$163.54 Million
Enterprise Value$165.62 Million
Earnings per Share$0.22
Beta2.09
Outstanding Shares79,149,000

Return

Return on Equity12.33%ROE
Return on Assets9.42%
Return on Invested Capital5.54%

Valuation & Multiples

P/E Ratio16.31P/E Ratio
PEG-12.98PEG
Price to Sales-Price to Sales
Price to Book Ratio2.04Price to Book Ratio
Enterprise Value to Revenue2.91
Enterprise Value to EBIT32.57
Enterprise Value to Net Income16
Total Debt to Enterprise0.01
Debt to Equity0.03Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 4, 2026
EPS
-$0.01
Est. -$0.01
Revenue
$27.19 M
Est. $30.22 M

Next Earnings Call

Expected Date
March 3, 2027
EPS Estimate
-$0.04
Consensus analyst estimate
Revenue Estimate
$29.93 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Chromadex Corp

117 employees
CEO: Robert Fried

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solut...